292621-45-5

Basic information

• Product Name: 4-BROMO-2-FLUOROBENZAMIDE
• Synonyms: BUTTPARK 81\01-02;4-BROMO-2-FLUOROBENZAMIDE;Benzamide, 4-bromo-2-fluoro-
• CAS NO: 292621-45-5
• Molecular Formula: C₇H₅BrFNO
• Molecular Weight: 218.02
• Mol File: 292621-45-5.mol

Chemical Properties

• Melting Point: 151-153℃
• Boiling Point: 261 °C at 760 mmHg
• Flash Point: 111.6 °C
• Appearance: /
• Density: 1.696 g/cm³
• Vapor Pressure: 0.0119mmHg at 25°C
• Refractive Index: 1.581
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: DMSO, Methanol
• PKA: 14.98±0.50(Predicted)
• CAS DataBase Reference: 4-BROMO-2-FLUOROBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-FLUOROBENZAMIDE(292621-45-5)
• EPA Substance Registry System: 4-BROMO-2-FLUOROBENZAMIDE(292621-45-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 292621-45-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-BROMO-2-FLUOROBENZAMIDE is used as a reagent for the synthesis of tricyclic dihydroquinazolinones, which are compounds that act as anti-obesity agents. These agents help in the development of medications aimed at treating obesity and its associated health issues.
4-BROMO-2-FLUOROBENZAMIDE is also used as a reagent for the synthesis of imidazole pyrimidine amides, compounds that act as cyclin-dependent kinase (CDK) inhibitors. CDK inhibitors are important in the development of cancer therapeutics, as they can help regulate cell cycle progression and prevent the uncontrolled growth of cancer cells.

InChI:InChI=1/C7H5BrFNO/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3H,(H2,10,11)

Upstream product

• 105942-08-3 4-bromo-6-fluorobenzonitrile 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 7664-41-7 ammonia 

Downstream Products

• 845306-17-4 5-(4-bromo-2-fluorophenyl)-3-methyl-1,2,4-oxadiazole 
• 845306-18-5 C₁₁H₁₂BrFN₂O 
• 957346-57-5 2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1221408-00-9 C₁₀H₁₁BrN₂O 
• 1242137-20-7 2-(4-carbamoyl-3-fluorophenylamino)-2-methylpropanoic acid 
• 1269646-51-6 (E)-4-bromo-N-((dimethylamino)methylene)-2-fluorobenzamide 
• 1228014-45-6 5-(4-bromo-2-fluorophenyl)-1H-1,2,4-triazole 
• 1269646-54-9 3-(4-bromo-2-fluorophenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole 
• 1269646-55-0 5-(4-bromo-2-fluorophenyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-1,2,4-triazole 
• 1269643-46-0 (S)-3-(3-(3-fluoro-4-(1H-1,2,4-triazol-3-yl)phenyl)pyrazolo[1,5-a]pyrimidin-5-yl)-4-isopropyloxazolidin-2-one 
• 915087-33-1 enzalutamide 
• 1289942-66-0 2-((3-fluoro-4-(methylcarbamoyl)phenyl)amino)-2-methyl propanoic acid 

Relevant articles and documents

Substrate Profiling of the Cobalt Nitrile Hydratase from Rhodococcus rhodochrous ATCC BAA 870

The aromatic substrate profile of the cobalt nitrile hydratase from Rhodococcus rhodochrous ATCC BAA 870 was evaluated against a wide range of nitrile containing compounds (>60). To determine the substrate limits of this enzyme, compounds ranging in size from small (90 Da) to large (325 Da) were evaluated. Larger compounds included those with a biaryl axis, prepared by the Suzuki coupling reaction, Morita–Baylis–Hillman adducts, heteroatomlinked diarylpyridines prepared by Buchwald–Hartwig crosscoupling reactions and imidazo[1,2a]pyridines prepared by the Groebke–Blackburn–Bienaymé multicomponent reaction. The enzyme active site was moderately accommodating, accepting almost all of the small aromatic nitriles, the diarylpyridines and most of the biaryl compounds and Morita–Baylis–Hillman products but not the Groebke–Blackburn–Bienaymé products. Nitrile conversion was influenced by steric hindrance around the cyano group, the presence of electron donating groups (e.g., methoxy) on the aromatic ring, and the overall size of the compound.

TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

AROMATIC HETEROCYCLIC COMPOUND

The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncology disease indications. The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. It is expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.

SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS

Compounds of Formula I: and salts thereof in which R1, R2, R2a, R3, n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.

MTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE MTOR/P13K/AKT PATHWAY

Provided herein are Heteroaryl Compounds having the following structure: R2 N (I) or (II) wherein R1 -R4 are as defined herein, compositions comprising an effective amount of a Heteroaryl Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, neurodegenerative diseases, diabetes, obesity, neurological disorders, age-related diseases, or cardiovascular conditions, comprising administering an effective amount of a Heteroaryl Compound to a patient in need thereof.

SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS

Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.

COMPOUNDS THAT ARE ERK INHIBITORS

Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydopyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 inhibition and potent in vitro anti-proliferative effects against cancer cell lines. Control of overall lipophilicity was important to achieve good in vitro potency along with acceptable physiochemical properties and margins against inhibition of both CYP isoforms and the hERG potassium ion channel. A compound with an attractive overall balance of properties was profiled in vivo and possessed suitable physiochemical and pharmacokinetic profiles for oral dosing.